5.54
Taysha Gene Therapies Inc (TSHA) 最新ニュース
TSHA|Taysha Gene Therapies Inc|Price:5.520|Chg%:-0.310 - TradingKey
Taysha Gene Therapies Inc (TSHA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Taysha Gene Therapies Inc (TSHA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Taysha Gene Therapies Inc (TSHA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TSHA|Taysha Gene Therapies Inc|Price:5.540|Chg%:+0.020 - TradingKey
Taysha Gene Therapies Inc (TSHA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TSHA Maintains Buy Rating -- Price Target Raised to $13.00 by Go - GuruFocus
Goldman Sachs Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $13 - Moomoo
Taysha Gene Therapies (TSHA) is One of The Most Affordable Biotech Names to Invest In - Yahoo Finance
Taysha Gene Therapies (TSHA) Experiences Significant Decline - GuruFocus
Taysha Gene Therapies Insider Sold Shares Worth $1,248,000, According to a Recent SEC Filing - Moomoo
Taysha's R&D Chief Sold $1.2 Million in Stock After a 149% Run - The Motley Fool
Taysha Gene Therapies president sells $1.25m in stock By Investing.com - Investing.com India
Insider Sell: Sukumar Nagendran Sells 200,000 Shares of Taysha G - GuruFocus
Insider Sell: Sukumar Nagendran Sells 200,000 Shares of Taysha Gene Therapies Inc (TSHA) - GuruFocus
Taysha Gene Therapies president sells $1.25m in stock - Investing.com
Taysha Gene Therapies (NASDAQ: TSHA) R&D chief sells 200,000 shares under plan - Stock Titan
Form 144 Taysha Gene Therapies For: 10 July By Investing.com - Investing.com Nigeria
Taysha Gene Therapies (TSHA) investor files to sell 200,000 shares via Jefferies - Stock Titan
Will Russell Index Removals and New Rett Data Change Taysha Gene Therapies' (TSHA) Narrative? - simplywall.st
TSHA Q1 2026 Earnings: EPS Miss of -$0.12 vs. -$0.0996 Estimate; Stock Declines MarginallyManagement Guidance Update - dars.gov.et
If You Invested $1,000 in Taysha Gene Therapies, Inc. (TSHA) - Stock Titan
Neurogene: 'Hold' EMBOLDEN Study Underway And 2nd Half 2027 Topline Data - Seeking Alpha
Citizens reiterates Taysha Gene Therapies stock rating on therapy progress By Investing.com - Investing.com India
Citizens reiterates Taysha Gene Therapies stock rating on therapy progress - Investing.com
Taysha’s TSHA-102 Rett Data Links Clinical Promise To Future Revenue - Sahm
A Quick Look at Today's Ratings for Taysha Gene Therapies(TSHA.US), With a Forecast Between $12 to $15 - Moomoo
BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Enterprise value to EBITDA forward of Taysha Gene Therapies, Inc. – NASDAQ:TSHA - TradingView
TSHA Maintained by Needham -- Price Target Holds at $12.00 - GuruFocus
Enterprise value to EBITDA forward of Taysha Gene Therapies, Inc. – BOATS:TSHA - TradingView
Price to sales forward of Taysha Gene Therapies, Inc. – NASDAQ:TSHA - TradingView
TSHA Maintained by Baird -- Price Target Raised to $15.00 - GuruFocus
Taysha: 'Buy' On Interim Analysis Of TSHA-102 First Half 2027 And Broad Label Potential - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
Baird Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $15 - Moomoo
Price to sales forward of Taysha Gene Therapies, Inc. – BOATS:TSHA - TradingView
Price to book forward of Taysha Gene Therapies, Inc. – NASDAQ:TSHA - TradingView
Enterprise value to EBIT forward of Taysha Gene Therapies, Inc. – BOATS:TSHA - TradingView
Price to earnings forward of Taysha Gene Therapies, Inc. – BOATS:TSHA - TradingView
Taysha Gene Therapies, Inc. Stock 12‑Month Price Target Raised to $13, Implies 105% Upside - TradingView
Taysha Gene Therapies, Inc.(NasdaqGS:TSHA) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Taysha Gene Therapies, Inc.(NasdaqGS: TSHA) dropped from Russell 3000E Index - marketscreener.com
Taysha Gene Therapies, Inc.(NasdaqGS: TSHA) dropped from Russell Microcap Index - marketscreener.com
Taysha Gene Therapies, Inc.(NasdaqGS:TSHA) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Taysha Gene Therapies launches $200M public offering; shares down - MSN
Taysha Gene Therapies Inc (TSHA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting - The Manila Times
Taysha Gene Therapies shares tumble following pricing shares at $6.00 to raise $200M - MSN
Form 424B5 Taysha Gene Therapies Inc For: 25 June By Investing.com - Investing.com Nigeria
Taysha Gene Therapies to present Rett syndrome data at conference By Investing.com - Investing.com Nigeria
大文字化:
|
ボリューム (24 時間):